HORIZON-HLTH-2022-DISEASE-06-03-two-stage
HORIZON-HLTH-2022-DISEASE-06-03-two-stage
Programme: Horizon Europe
9 projects · €61,446,996 total EU contribution (project-level) · 80 participating organizations · 24 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€61,446,996
Countries active
Participant organizations by country (headquarters in CORDIS).
- UK (10)
- BE (9)
- Germany (7)
- Netherlands (7)
- CH (6)
- France (6)
- Spain (5)
- Italy (5)
- PT (4)
- CZ (3)
- AU (2)
- IE (2)
- SE (2)
- US (2)
- AT (1)
- DK (1)
- ET (1)
- GA (1)
- HR (1)
- HU (1)
- IN (1)
- MT (1)
- NO (1)
- UG (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- Leiden University Medical Center4 projects · NL
- UOXF4 projects · UK
- VACCINE FORMULATION INSTITUTE(CH)LTD4 projects · CH
- EUROPEAN VACCINE INITIATIVE3 projects · DE
- SSI3 projects · DK
- INSERM2 projects · FR
- IP2 projects · FR
- IPL2 projects · FR
- LINQ MANAGEMENT GMBH2 projects · DE
- LSHTM2 projects · UK
- MHRA2 projects · UK
- NOVAVAX AB2 projects · SE
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
CorrelAtes of Protective immuniTy-driven Investigation of malaria VAccine combinaTion stratEgies CAPTIVATE · 101081028 | HORIZON | €8,725,948 | €646,164 | Details |
Optimising a High Efficacy Plasmodium vivax Malaria Vaccine OptiViVax · 101080744 | HORIZON | €3,826,044 | €451,536 | Details |
Intranasal, rapid-acting vaccine for all seasonal and pandemic influenza viruses FLUniversal · 101080692 | HORIZON | €7,567,788 | €1,840,439 | Details |
A Vaccine Targeting Eradication of Malaria UltiMalVax · 101080928 | HORIZON | €2,620,000 | €238,750 | Details |
INNOVATIVE NASAL VACCINES TO PREVENT PATHOGEN COLONIZATION AND INFECTION IN THE UPPER RESPIRATORY TRACT NOSEVAC · 101080528 | HORIZON | €7,369,449 | €1,023,040 | Details |
Immunopeptidomics-based Development of Next-Generation Bacterial mRNA Vaccines BAXERNA 2.0 · 101080544 | HORIZON | €9,458,801 | €0 | Details |
Improving understanding of lung immunity in tuberculosis to establish a diverse, innovative TB vaccine pipeline targeting mucosal immunity TBVAC-HORIZON · 101080309 | HORIZON | €6,183,822 | €0 | Details |
NEXT GENERATION VACCINES AGAINST GASTROINTESTINAL MUCOSAL PATHOGENS, USING HELICOBACTER PYLORI AS MODEL PATHOGEN Vax2Muc · 101080486 | HORIZON | €8,219,843 | €0 | Details |
Innovations for vaccines against helminth infections WORMVACS2.0 · 101080784 | HORIZON | €7,475,302 | €714,093 | Details |